Michael LaRosa was Jill Biden's press secretary for the first 18 months of Joe Biden's presidency, and in recent weeks he's ...

SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced data ...

With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

Pliant Therapeutics, Inc.’s PLRX share price has surged by 10.39%, which has investors questioning if this is right time to ...

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

New York, New York-- (Newsfile Corp. - March 17, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is ...

Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested ...

Pliant is committed to the development of its other clinical and pipeline assets including PLN-101095 in oncology. The Company is currently enrolling the fourth of five planned dose cohorts in a ...

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that ...

President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell ...

AlphaQuest LLC lowered its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 73.9% during the 4th quarter, ...